YORVIPATH

Product Overview

About YORVIPATH

YORVIPATH is a prescription medication containing the active ingredient palopegteriparatide, a recombinant form of human parathyroid hormone (PTH) analog. It is used for the treatment of osteoporosis in adult patients at high risk of fracture.

Key Benefits & Uses

• Treatment of osteoporosis in adult patients at high risk of fracture
• Increases bone mineral density and reduces the risk of vertebral and non-vertebral fractures
• May be used in patients with a history of osteoporotic fractures or multiple myeloma

Active Ingredient & Action

Palopegteriparatide, the active ingredient in YORVIPATH, works by stimulating bone growth and increasing bone mineral density. It mimics the action of human parathyroid hormone, which plays a crucial role in regulating calcium levels and bone metabolism. By activating the PTH receptor, palopegteriparatide promotes osteoblast activity, leading to increased bone formation and reduced bone resorption.

Important Notes

YORVIPATH is available in pre-filled syringes for subcutaneous injection. It is essential to follow the recommended dosing schedule and administration instructions provided by your healthcare provider. Regular monitoring of calcium levels, vitamin D levels, and bone mineral density is recommended during treatment. As with any medication, potential side effects may include injection site reactions, dizziness, and nausea. Consult your healthcare provider for more information on the safe use of YORVIPATH.